Blocking TACI signaling in mice with chronic lymphocytic leukemia reduces tumor size, returns IL-6 and IL-10 cytokine levels to normal, restores T-cell populations, and lowers PD-L1 and PD-L2...
Mechanism
Synthesis from 1 study
Blocking TACI stops leukemia cells from producing chemicals that hide them from immune cells and prevent T cells from working. This lets T cells find and kill the cancer cells, and stops the cancer from gathering in the spleen to hide. Tumor growth slows because the immune system can now fight back.
Most probable mechanism
When TACI is blocked, cancer cells in the blood can't send survival signals that turn on harmful chemicals. This stops the cancer cells from moving to the spleen and hiding from immune cells. Without these signals, the cancer cells stop producing molecules that shut down T cells and release fewer immune-suppressing chemicals. As a result, T cells wake up, attack the cancer, and reduce tumor growth.
TACI receptor is blocked, preventing binding of BAFF and APRIL ligands
Loss of TACI signaling reduces NF-κB pathway activation in chronic lymphocytic leukemia cells
Downregulation of NF-κB target genes reduces production of IL-6, IL-10, PD-L1, and PD-L2
Reduced immunosuppressive molecules and cytokines remove inhibition of T-cell activation and proliferation
Impaired migration of leukemia cells to the spleen disrupts formation of an immunosuppressive niche
Restored T-cell function enables direct recognition and elimination of leukemia cells
Evidence from Studies
Supporting (1)
Community contributions welcome
Abstract PR-06: Disrupting TACI signaling to restore immune balance: harnessing translational opportunities at the intersection of cancer and autoimmunity
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.